These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 21702057)

  • 1. Stevens-Johnson syndrome after lenalidomide therapy for multiple myeloma: a case report and a review of treatment options.
    Allegra A; Alonci A; Penna G; Russo S; Gerace D; Greve B; D'Angelo A; Catena S; Musolino C
    Hematol Oncol; 2012 Mar; 30(1):41-5. PubMed ID: 21702057
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Possible lenalidomide-induced Stevens-Johnson syndrome during treatment for multiple myeloma.
    Boruah PK; Bolesta S; Shetty SM
    Pharmacotherapy; 2011 Sep; 31(9):925. PubMed ID: 21923596
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Stevens-Johnson syndrome induced by combination of imatinib and allopurinol.
    Hsieh HJ; Chan AL; Lin SJ
    Chemotherapy; 2009; 55(4):197-9. PubMed ID: 19439939
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term complete remission in a multiple myeloma patient after Stevens-Johnson syndrome due to lenalidomide therapy.
    Musolino C; Alonci A; Catena S; Rizzotti P; Russo S; Rotondo F; Allegra A
    Acta Oncol; 2013 Jun; 52(5):1050-1. PubMed ID: 23113590
    [No Abstract]   [Full Text] [Related]  

  • 5. Lenalidomide cutaneous adverse event: a case of Stevens-Johnson syndrome (SJS) in a primary plasma cell leukaemia patient treated with lenalidomide and dexamethasone.
    Siniscalchi A; Tendas A; Morino L; Dentamaro T; De Bellis A; Perrotti A; de Fabritiis P; Musto P; Caravita T
    Support Care Cancer; 2012 Jul; 20(7):1585-7. PubMed ID: 22562584
    [No Abstract]   [Full Text] [Related]  

  • 6. Lenalidomide and its role in the management of multiple myeloma.
    Falco P; Cavallo F; Larocca A; Liberati AM; Musto P; Boccadoro M; Palumbo A
    Expert Rev Anticancer Ther; 2008 Jun; 8(6):865-74. PubMed ID: 18533796
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Stevens-Johnson/toxic epidermal necrolysis overlap syndrome following lenalidomide treatment for multiple myeloma relapse after allogeneic transplantation.
    Wäsch R; Jakob T; Technau K; Finke J; Engelhardt M
    Ann Hematol; 2012 Feb; 91(2):287-9. PubMed ID: 21494796
    [No Abstract]   [Full Text] [Related]  

  • 8. Review of therapy for relapsed/refractory multiple myeloma: focus on lenalidomide.
    Mariz JM; Esteves GV
    Curr Opin Oncol; 2012 Jan; 24 Suppl 2():S3-11. PubMed ID: 22245806
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lenalidomide in combination with dexamethasone for the treatment of relapsed or refractory multiple myeloma.
    Palumbo A; Dimopoulos M; San Miguel J; Harousseau JL; Attal M; Hussein M; Knop S; Ludwig H; von Lilienfeld-Toal M; Sonneveld P
    Blood Rev; 2009 Mar; 23(2):87-93. PubMed ID: 18774632
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The potential benefits of participating in early-phase clinical trials in multiple myeloma: long-term remission in a patient with relapsed multiple myeloma treated with 90 cycles of lenalidomide and bortezomib.
    Richardson PG; Laubach JP; Schlossman RL; Ghobrial IM; Redman KC; McKenney M; Warren D; Noonan K; Lunde L; Doss D; Colson K; Hideshima T; Mitsiades C; Munshi NC; Anderson KC
    Eur J Haematol; 2012 May; 88(5):446-9. PubMed ID: 22300348
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lenalidomide in the treatment of multiple myeloma: a review.
    Armoiry X; Aulagner G; Facon T
    J Clin Pharm Ther; 2008 Jun; 33(3):219-26. PubMed ID: 18452408
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lenalidomide: new drug. Myeloma: many questions remain unanswered.
    Prescrire Int; 2008 Dec; 17(98):230-2. PubMed ID: 19422142
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lenalidomide-induced myelosuppression is associated with renal dysfunction: adverse events evaluation of treatment-naïve patients undergoing front-line lenalidomide and dexamethasone therapy.
    Niesvizky R; Naib T; Christos PJ; Jayabalan D; Furst JR; Jalbrzikowski J; Zafar F; Mark T; Lent R; Pearse RN; Ely S; Leonard JP; Mazumdar M; Chen-Kiang S; Coleman M
    Br J Haematol; 2007 Sep; 138(5):640-3. PubMed ID: 17686058
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combined pegylated liposomal doxorubicin and bortezomib is highly effective in patients with recurrent or refractory multiple myeloma who received prior thalidomide/lenalidomide therapy.
    Sonneveld P; Hajek R; Nagler A; Spencer A; Bladé J; Robak T; Zhuang SH; Harousseau JL; Orlowski RZ;
    Cancer; 2008 Apr; 112(7):1529-37. PubMed ID: 18300257
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Management of the adverse effects of lenalidomide in multiple myeloma.
    González Rodríguez AP
    Adv Ther; 2011 Mar; 28 Suppl 1():1-10. PubMed ID: 21431626
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lenalidomide in combination with dexamethasone for the treatment of multiple myeloma after one prior therapy.
    Hazarika M; Rock E; Williams G; Dagher R; Sridhara R; Booth B; Farrell A; Justice R; Pazdur R
    Oncologist; 2008 Oct; 13(10):1120-7. PubMed ID: 18922829
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Management of older patients with multiple myeloma.
    Gay F; Palumbo A
    Blood Rev; 2011 Mar; 25(2):65-73. PubMed ID: 21295387
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Melphalan, prednisone, and lenalidomide treatment for newly diagnosed myeloma: a report from the GIMEMA--Italian Multiple Myeloma Network.
    Palumbo A; Falco P; Corradini P; Falcone A; Di Raimondo F; Giuliani N; Crippa C; Ciccone G; Omedè P; Ambrosini MT; Gay F; Bringhen S; Musto P; Foà R; Knight R; Zeldis JB; Boccadoro M; Petrucci MT;
    J Clin Oncol; 2007 Oct; 25(28):4459-65. PubMed ID: 17785703
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lenalidomide in multiple myeloma: current role and future directions.
    Zeldis JB; Knight RD; Jacques C; Tozer A; Bizzari JP
    Expert Opin Pharmacother; 2010 Apr; 11(5):829-42. PubMed ID: 20210686
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Thalidomide and lenalidomide in multiple myeloma.
    Mazumder A; Jagannath S
    Best Pract Res Clin Haematol; 2006; 19(4):769-80. PubMed ID: 16997182
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.